PanTera focuses on enabling personalized tumor treatment through radiopharmaceuticals by securing the large-scale production of actinium-225 (Ac-225). This alpha-emitting radioisotope is essential for Targeted RadioTherapy (TRT) applications in oncology. The company's efforts aim to increase the accessibility of innovative cancer therapies based on Ac-225 and theranostics.
Funding
$148.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ELFounders
Product
Problem
The limited availability of actinium-225 (Ac-225) constrains the widespread adoption of targeted alpha therapy (TAT) for cancer treatment. This shortage hinders the development and accessibility of personalized radiopharmaceuticals, which offer a precise method for destroying cancerous tumors while minimizing damage to healthy tissue.
Solution
PanTera focuses on the large-scale production of high-purity actinium-225 (Ac-225) to enable broader access to targeted alpha therapy (TAT) for cancer patients. By increasing the supply of this critical radioisotope, PanTera facilitates the development and commercialization of innovative radiopharmaceuticals and theranostics. The company aims to provide a reliable source of Ac-225, empowering researchers and clinicians to advance personalized cancer treatments that utilize the potent alpha-emitting properties of Ac-225 to selectively target and eradicate tumors. PanTera's efforts are directed towards improving the accessibility of these therapies, ultimately offering new hope for patients with various types of cancer.
Target Audience
The primary target audience includes pharmaceutical companies, hospitals, and research institutions involved in the development and application of targeted alpha therapies for cancer treatment.
Features
- Large-scale production of actinium-225 (Ac-225)
- High-purity Ac-225 for targeted radiopharmaceutical development
- Support for targeted alpha therapy (TAT) research and clinical applications
- Aim to improve the accessibility of Ac-225 based cancer therapy and theranostics